{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:09:40Z","timestamp":1780106980026,"version":"3.54.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001516","name":"National Heart Foundation of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001516","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013500","name":"Diabetestutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005104","name":"Australian Institute of Health and Welfare, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.diabres.2026.113168","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T16:10:04Z","timestamp":1771690204000},"page":"113168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Chronic complication risk and benefits of fenofibrate in type 2 diabetes by a PPAR\u03b1 polymorphism (rs6008845, C\/T): a FIELD trial substudy"],"prefix":"10.1016","volume":"234","author":[{"given":"Andrzej S.","family":"Januszewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.H.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abubakar Siddiq","family":"Mangani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok Leung","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Strbenac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Donoghoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke M.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell S.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"John Simes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia J.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Keech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9500","key":"10.1016\/j.diabres.2026.113168_b0005","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.diabres.2026.113168_b0010","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.diabres.2026.113168_b0015","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"N Engl J Med"},{"issue":"9600","key":"10.1016\/j.diabres.2026.113168_b0020","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.diabres.2026.113168_b0025","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the fenofibrate intervention and event lowering in diabetes (FIELD) study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2026.113168_b0030","doi-asserted-by":"crossref","unstructured":"Jenkins AJ, O'Connell RL, Januszewski AS, Webster AC, T MED, Jardine MJ, et al. Not enough known about fenofibrate's kidney effects in people with Type 2 diabetes. Diabetes Res Clin Pract. 2024;210:111612.","DOI":"10.1016\/j.diabres.2024.111612"},{"issue":"2","key":"10.1016\/j.diabres.2026.113168_b0035","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2337\/dc11-1109","article-title":"Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study","volume":"35","author":"Ting","year":"2012","journal-title":"Diabetes Care"},{"issue":"9677","key":"10.1016\/j.diabres.2026.113168_b0040","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0140-6736(09)60698-X","article-title":"Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial","volume":"373","author":"Rajamani","year":"2009","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.diabres.2026.113168_b0045","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400179","article-title":"Effect of fenofibrate on progression of diabetic retinopathy","volume":"3","author":"Preiss","year":"2024","journal-title":"NEJM Evid"},{"issue":"2","key":"10.1016\/j.diabres.2026.113168_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087327","article-title":"Regulation of fatty acid oxidation in mouse cumulus-oocyte complexes during maturation and modulation by PPAR agonists","volume":"9","author":"Dunning","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.diabres.2026.113168_b0055","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.diabres.2026.113168_b0060","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jhep.2011.12.008","article-title":"PPARalpha activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats","volume":"56","author":"Rodriguez-Vilarrupla","year":"2012","journal-title":"J Hepatol"},{"issue":"16","key":"10.1016\/j.diabres.2026.113168_b0065","doi-asserted-by":"crossref","first-page":"16154","DOI":"10.1074\/jbc.M400346200","article-title":"Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate","volume":"279","author":"Gervois","year":"2004","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.diabres.2026.113168_b0070","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/db19-0973","article-title":"PPARA polymorphism influences the cardiovascular benefit of fenofibrate in Type 2 diabetes: findings from ACCORD-lipid","volume":"69","author":"Morieri","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2026.113168_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1074911","article-title":"PPARalpha: an emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases","volume":"13","author":"Lin","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.diabres.2026.113168_b0080","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the fenofibrate intervention and event lowering in diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"issue":"5B","key":"10.1016\/j.diabres.2026.113168_b0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0002-9343(87)90866-7","article-title":"Fibric acids: effects on lipids and lipoprotein metabolism","volume":"83","author":"Grundy","year":"1987","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.diabres.2026.113168_b0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/clp.10.84","article-title":"The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus","volume":"6","author":"Elam","year":"2011","journal-title":"Clin Lipidol"},{"issue":"7571","key":"10.1016\/j.diabres.2026.113168_b0095","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"1000 Genomes Project","year":"2015","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.diabres.2026.113168_b0100","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.molmet.2014.02.002","article-title":"Integrated physiology and systems biology of PPARalpha","volume":"3","author":"Kersten","year":"2014","journal-title":"Mol Metab"},{"issue":"4","key":"10.1016\/j.diabres.2026.113168_b0105","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2231-4040.90879","article-title":"The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases","volume":"2","author":"Tyagi","year":"2011","journal-title":"J Adv Pharm Technol Res"},{"issue":"10","key":"10.1016\/j.diabres.2026.113168_b0110","article-title":"Roles of oxidative stress and inflammation in vascular endothelial dysfunction-related disease","volume":"11","author":"Higashi","year":"2022","journal-title":"Antioxidants (Basel)"},{"issue":"4","key":"10.1016\/j.diabres.2026.113168_b0115","article-title":"Inflammation-induced nitric oxide suppresses PPARalpha expression and function via downregulation of Sp1 transcriptional activity in adipocytes","volume":"1866","author":"Kwon","year":"2023","journal-title":"Biochim Biophys Acta"},{"issue":"38","key":"10.1016\/j.diabres.2026.113168_b0120","doi-asserted-by":"crossref","first-page":"15401","DOI":"10.1073\/pnas.1307211110","article-title":"Pathogenic role of diabetes-induced PPAR-alpha down-regulation in microvascular dysfunction","volume":"110","author":"Hu","year":"2013","journal-title":"PNAS"},{"key":"10.1016\/j.diabres.2026.113168_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphys.2024.100133","article-title":"How PPAR-alpha mediated inflammation may affect the pathophysiology of chronic kidney disease","volume":"8","author":"Masenga","year":"2025","journal-title":"Curr Res Physiol"},{"issue":"5","key":"10.1016\/j.diabres.2026.113168_b0130","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","article-title":"Molecular actions of PPARalpha in lipid metabolism and inflammation","volume":"39","author":"Bougarne","year":"2018","journal-title":"Endocr Rev"},{"issue":"18","key":"10.1016\/j.diabres.2026.113168_b0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184378","article-title":"Impact of PPAR-alpha polymorphisms-the case of metabolic disorders and atherosclerosis","volume":"20","author":"Ruscica","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.diabres.2026.113168_b0140","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s00109-005-0678-9","article-title":"Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?","volume":"83","author":"Peters","year":"2005","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.diabres.2026.113168_b0145","doi-asserted-by":"crossref","first-page":"e002","DOI":"10.1621\/nrs.08002","article-title":"PPARalpha: energy combustion, hypolipidemia, inflammation and cancer","volume":"8","author":"Pyper","year":"2010","journal-title":"Nucl Recept Signal"},{"issue":"4","key":"10.1016\/j.diabres.2026.113168_b0150","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/carcin\/bgx023","article-title":"PPARalpha regulates tumor cell proliferation and senescence via a novel target gene carnitine palmitoyltransferase 1C","volume":"38","author":"Chen","year":"2017","journal-title":"Carcinogenesis"},{"issue":"42","key":"10.1016\/j.diabres.2026.113168_b0155","doi-asserted-by":"crossref","first-page":"44635","DOI":"10.18632\/oncotarget.5988","article-title":"PPARalpha induces cell apoptosis by destructing Bcl2","volume":"6","author":"Gao","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.diabres.2026.113168_b0160","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1161\/01.RES.0000150594.95988.45","article-title":"Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties","volume":"95","author":"Teissier","year":"2004","journal-title":"Circ Res"},{"issue":"6","key":"10.1016\/j.diabres.2026.113168_b0165","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4330\/wjc.v5.i6.164","article-title":"Peroxisome-proliferator-activated receptors regulate redox signaling in the cardiovascular system","volume":"5","author":"Kim","year":"2013","journal-title":"World J Cardiol"},{"issue":"2","key":"10.1016\/j.diabres.2026.113168_b0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26020736","article-title":"Discovery of PPAR alpha lipid pathway modulators that do not bind directly to the receptor as potential anti-cancer compounds","volume":"26","author":"Al Subait","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabres.2026.113168_b0175","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/830501","article-title":"PPAR-gamma agonists and their effects on IGF-I receptor signaling: implications for cancer","volume":"2009","author":"Belfiore","year":"2009","journal-title":"PPAR Res"},{"key":"10.1016\/j.diabres.2026.113168_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.599995","article-title":"PPAR-alpha modulators as current and potential cancer treatments","volume":"11","author":"Tan","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.diabres.2026.113168_b0185","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/542359","article-title":"The role of PPARalpha activation in liver and muscle","volume":"2010","author":"Burri","year":"2010","journal-title":"PPAR Res"},{"issue":"17","key":"10.1016\/j.diabres.2026.113168_b0190","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Accord Study Group","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.diabres.2026.113168_b0195","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ahj.2011.12.004","article-title":"Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: the Fenofibrate intervention and Event Lowering in Diabetes (FIELD) study","volume":"163","author":"Tonkin","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.diabres.2026.113168_b0200","doi-asserted-by":"crossref","unstructured":"Rogers A, Beck A, Tintle NL. Evaluating the concordance between sequencing, imputation and microarray genotype calls in the GAW18 data. BMC Proc. 2014;8(Suppl 1 Genetic Analysis Workshop 18Vanessa Olmo):S22.","DOI":"10.1186\/1753-6561-8-S1-S22"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726000872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726000872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:46:05Z","timestamp":1780105565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726000872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":40,"alternative-id":["S0168822726000872"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113168","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic complication risk and benefits of fenofibrate in type 2 diabetes by a PPAR\u03b1 polymorphism (rs6008845, C\/T): a FIELD trial substudy","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113168"}}